%0 Journal Article
%A Graef, Josefine
%A Bluemel, Stephanie
%A Brenner, Winfried
%A Amthauer, Holger
%A Truckenmueller, Peter
%A Kaul, David
%A Vajkoczy, Peter
%A Onken, Julia S
%A Furth, Christian
%T [177Lu]Lu-PSMA Therapy as an Individual Treatment Approach for Patients with High-Grade Glioma: Dosimetry Results and Critical Statement.
%J Journal of nuclear medicine
%V 64
%N 6
%@ 0097-9058
%C New York, NY
%I Soc.
%M DKFZ-2023-00852
%P 892-895
%D 2023
%Z 2023 Jun;64(6):892-895
%X The theranostic use of prostate-specific membrane antigen (PSMA) appears to be promising in patients with high-grade glioma. This study investigated [177Lu]Lu-PSMA therapy as an individual treatment approach with a focus on intratherapeutic dosimetry. Methods: Three patients were treated with a median of 6.03 GBq (interquartile range [IQR], 5.74-6.10) of [177Lu]Lu-PSMA. Intratherapeutic dosimetry was performed using a hybrid scenario with planar whole-body scintigraphy at 2, 24, and 48 h after treatment injection and SPECT/CT at 48 h after injection. Additive whole-body scintigraphy at 8 d after injection was performed on 1 patient. Results: The median doses were 0.56 Gy (IQR, 0.36-1.25 Gy) to tumor, 0.27 Gy (IQR, 0.16-0.57 Gy) to risk organs, 2.13 Gy (IQR, 1.55-2.89 Gy) to kidneys, and 0.76 Gy (IQR, 0.70-1.20 Gy) to salivary glands. Whole-body exposure was 0.11 Gy (IQR, 0.06-0.18 Gy). Conclusion: Because the intratherapeutic tumor dose is lower than that used in external radiation oncology, the effectiveness of treatment is questionable.
%K PET/MRI (Other)
%K [177Lu]Lu-PSMA (Other)
%K [68Ga]Ga-PSMA (Other)
%K glioma (Other)
%K theranostics (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:37116918
%R 10.2967/jnumed.122.264850
%U https://inrepo02.dkfz.de/record/275753